A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines

International Immunopharmacology, Год журнала: 2021, Номер 100, С. 108162 - 108162

Опубликована: Сен. 17, 2021

Язык: Английский

---

Current advances and challenges in mpox vaccine development: a global landscape

Therapeutic Advances in Vaccines and Immunotherapy, Год журнала: 2025, Номер 13

Опубликована: Янв. 1, 2025

Given the surge in mpox outbreaks 2022 and advancements domestic international vaccine research, effectiveness of smallpox vaccines providing cross-protection against remains crucial. Having learned from COVID-19 pandemic, it is significant to continue evaluating existing ensure their safety efficacy. Developing new for widespread use its emerging strains also serves as a preventive strategy ongoing battle this dynamic infection. Here's an opportunity control human-to-human transmission, give short deadlines, avoid disparity. Public health systems must take decisive action prevent global spread mpox, particularly among vulnerable groups. This should include strengthening surveillance, improving access, ensuring equitable distribution, resource-poor settings, future outbreaks. review aims assess recent barriers development, emphasizing distribution settings.

Язык: Английский

---

Vaccine development for mosquito-borne viral diseases

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Май 12, 2023

Mosquito-borne viral diseases are a group of illnesses that predominantly transmitted by mosquitoes, including viruses from the Togaviridae and Flaviviridae families. In recent years, outbreaks caused Dengue Zika family, Chikungunya virus have raised significant concerns for public health. However, there currently no safe effective vaccines available these viruses, except CYD-TDV, which has been licensed virus. Efforts to control transmission COVID-19, such as home quarantine travel restrictions, somewhat limited spread mosquito-borne diseases. Several vaccine platforms, inactivated vaccines, viral-vector live attenuated protein nucleic acid being developed combat viruses. This review analyzes various platforms against Dengue, Zika, provides valuable insights responding potential outbreaks.

Язык: Английский

---

mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review

Clinical and Experimental Medicine, Год журнала: 2024, Номер 24(1)

Опубликована: Янв. 27, 2024

Abstract Over the last 24 months, there has been growing evidence of a correlation between mRNA COVID-19 vaccine boosters and increased prevalence infection other pathologies. Recent works have added possible causation to correlation. may impair immune system response in compromised individuals. Multiple doses vaccines result much higher levels IgG 4 antibodies, or also impaired activation CD4 + CD8 T cells. The opportunity for needs careful consideration, as this impacts cost-to-benefit ratio boosters’ practice.

Язык: Английский

---

COVID-19 Vaccine Does Not Increase the Risk of Disease Flare-Ups among Patients with Autoimmune and Immune-Mediated Diseases

Journal of Personalized Medicine, Год журнала: 2021, Номер 11(12), С. 1283 - 1283

Опубликована: Дек. 2, 2021

Reports describing post-vaccine autoimmune phenomena, in previously healthy individuals, increased the concerns regarding risk of disease flare-ups patients with immune diseases. We aimed to assess potential flare-up, after receiving COVID-19 (Coronavirus 2019) vaccine, during a follow-up period 6 months.We performed prospective cohort study, enrolling autoimmune- and immune-mediated diseases who voluntarily completed our questionnaire, both online hospital evaluations. Based on their decision receive were divided into two groups (vaccinated non-vaccinated). Participants chose not vaccine served as control group terms flare-ups.A total 623 patients, 416 vaccinated 207 non-vaccinated, included study evaluations (222/623) (401/623) enrolment. There was no difference concerning flare-up between non-vaccinated (1.16, versus 1.72 flare-ups/100 patients-months, p = 0.245). The associated having more than one disease, previous past year.We did find an following vaccination autoimmune-/immune-mediated diseases, median 5.9 months. According results, there should be obvious reason for hesitancy among this category patients.

Язык: Английский

---

Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe

Journal of Clinical Medicine, Год журнала: 2021, Номер 10(22), С. 5338 - 5338

Опубликована: Ноя. 16, 2021

Optimization of COVID-19 vaccination rate among healthcare personnel is utmost priority to secure provision uninterrupted care and protect the most vulnerable patients. This study, as part global CoVaST project, aimed assess occurrence short-term adverse events (SRAEs) two administered vaccines, mRNA-based (Pfizer-BioNTech Moderna) viral vector-based (AstraZeneca) in sector workers (HWs).

Язык: Английский

---

Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis

Virology Journal, Год журнала: 2022, Номер 19(1)

Опубликована: Авг. 8, 2022

Abstract Background Immunocompromised (IC) patients are at higher risk of more severe COVID-19 infections than the general population. Special considerations should be dedicated to such patients. We aimed investigate efficacy vaccines based on vaccine type and etiology as well necessity booster dose in this high-risk Materials methods searched PubMed, Web Science, Scopus databases for observational studies published between June 1st, 2020, September 2021, which investigated seroconversion after administration adult with IC conditions. For investigation sources heterogeneity, subgroup analysis sensitivity were conducted. Statistical was performed using R software. Results According Preferred Reporting Items Systematic Reviews Meta-Analyses, we included 81 articles meta-analysis. The overall crude prevalence first (n: 7460), second 13,181), third 909, all population transplant mRNA administration) 26.17% (95% CI 19.01%, 33.99%, I 2 = 97.1%), 57.11% CI: 49.22%, 64.83%, 98.4%), 48.65% 34.63%, 62.79%, 94.4%). Despite relatively same immunogenicity vector-based dose, induced immunity dose. Regarding etiologic factor, less likely develop both rather malignancy (17.0% vs 37.0% P 0.02; 38.3% 72.1% < 0.001) or autoimmune disease 36.4%, 0.04; 80.2%, 0.001). To evaluate observed an increasing trend (17.0%), (38.3%), (48.6%) Conclusion rising pattern boosting tends promising. In case, attention devoted who possess lowest response rate.

Язык: Английский

---

Perceptions and experiences of COVID-19 vaccines’ side effects among healthcare workers at an Egyptian University Hospital: a cross-sectional study

Tropical Medicine and Health, Год журнала: 2022, Номер 50(1)

Опубликована: Май 30, 2022

Abstract Background A safe and effective vaccine is the ultimate key to mitigating COVID-19 pandemic. Vaccine acceptance influenced by various factors, including perceptions about vaccine’s safety side effects. The effects vary depending on type of vaccine, but they are mainly mild, local, temporary, self-limiting. Methods cross-sectional study was carried out at Tanta University Hospitals, 1246 healthcare workers who received either first or second dose selected via a systematic random sampling technique using self-administered structured validated questionnaire for data collection from November 2021 January 2022. Qualitative were presented as frequencies percentages analyzed Chi-square Fisher’s exact tests. Results prevalence one more 91.3%. Among participants, two-thirds believed in its necessity (65.4% 63.6%, respectively). Significantly participants (46.9%) concerned AstraZeneca thrombotic complications than other types. top five reported injection site pain (64.8%), sense fatigue (57.1%), headache (49.9%), muscle (48.7%), fever (46.5). Most significantly higher among vaccinated with AstraZeneca. Side impacted work capacity 23.4%, which (33.6%). Conclusion Participants had good level belief vaccination necessity. Healthcare got adverse vaccines. Injection pain, fatigue, headache, pains, most frequently More research needed understand long-term vaccinations better, improve public trust, accelerate adoption.

Язык: Английский

---

Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study

Vaccine, Год журнала: 2023, Номер 41(24), С. 3636 - 3646

Опубликована: Май 3, 2023

Data on the effectiveness of 3-dose mRNA-1273 primary series are limited, particularly in comparison to 2 doses. Given suboptimal COVID-19 vaccine uptake among immunocompromised populations, it is important monitor fewer than recommended doses this population. We conducted a matched cohort study at Kaiser Permanente Southern California evaluate relative (rVE) vs preventing SARS-CoV-2 infection and severe outcomes individuals. included 21,942 recipients who were 1:1 with randomly selected 2-dose (third accrued 08/12/2021–12/31/2021, follow-up through 01/31/2022). Adjusted rVE 3 against infection, hospitalization, hospital death 55.0 % (95 CI: 50.8–58.9 %), 83.0 (75.4–88.3 87.1 (30.6–97.6 respectively. Three associated significantly higher outcomes, compared These findings consistent across subgroups demographic clinical characteristics, mostly immunocompromising conditions. Our highlights importance completing for populations.

Язык: Английский

---

The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2

Cureus, Год журнала: 2023, Номер unknown

Опубликована: Сен. 20, 2023

The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and posed unprecedented challenges to healthcare systems around world. In wake of COVID-19's emergence 2019, a variety vaccine technologies were formulated developed, including those that drew from technology employed messenger RNA (mRNA) vaccines, designed curb disease's transmission manage pandemic. mRNA several advantages over traditional ones, hence its development received considerable attention recently. Researchers believe will emerge as leading because it is potent, inexpensive, rapidly safe. This article provides an overview vaccines special focus on efficacy safety Moderna Pfizer-BioNTech against different variants COVID-19 compare them Oxford-AstraZeneca (viral vector) Sinopharm (inactivated virus) vaccines. clinical data reviewed this demonstrate currently authorized are highly safe potent COVID-19, especially comparison

Язык: Английский

---